Project Grant HT94252410324

This federal Project Grant award, titled "MAINTENANCE RTMS FOR DEPRESSION (MAITR-DE)", is funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The $968,769 award will support a multi-site study to investigate the efficacy of maintenance repetitive transcranial magnetic stimulation (rTMS) in sustaining treatment response for individuals with treatment-resistant depression. The study will be conducted by the University of...

RADIANT Project Grant Summary The National Cancer Institute (NCI) awarded a $747,660 Project Grant to Sloan-Kettering Institute for Cancer Research on June 2, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and validate a scalable telemedicine-based intervention combining remote patient monitoring (RPM) and integrative medicine (IM) therapies for medical oncology patients following hospital discharge. The five-year project, scheduled for completion on May...

This $576,337 National Institute of Mental Health project grant funds research at Stanford University to evaluate a biomarker-guided intervention approach for anhedonia in treatment-resistant depression. The grant supports a clinical trial targeting D3 receptor agonism with pramipexole to determine its effects on ventral striatum brain activation as measured by functional neuroimaging. The study aims to enroll treatment-resistant depression patients with prominent anhedonia to evaluate whether...

This $2.9 million Defense Health Agency project grant funds research on suicide prevention among military personnel and veterans. The grant supports a multi-site randomized clinical trial through September 2026 to evaluate the efficacy of Written Exposure Therapy for Suicide Prevention compared to treatment as usual. Researchers at Boston University and partner institutions University of Colorado Denver and University of Texas Health Science Center San Antonio aim to reduce suicidal thoughts and...

This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...

The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...

This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,458,000.00 to The University of Texas MD Anderson Cancer Center to conduct research on "The Role of Androgens in Regulating Extracellular Vesicle Secretion and Molecular Cargo Loading by Prostate Cancer Cells." The 3-year project, beginning on March 1, 2024, aims to investigate how androgens, male sex hormones, influence the...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $731,503 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026 through May 31, 2031. This grant funds a randomized controlled trial (RCT) evaluating Brief Behavioral Activation (BBA) as a telehealth-delivered intervention for treating depression in older adult cancer survivors (OACS) aged 65 and older. The research addresses a...

This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...

This Project Grant award from the Defense Health Agency provides $825,000 in funding to Fundacio Privada Institut D Investigacio Oncologica De Vall-Hebron for studying intratumor heterogeneity in the evolution of metastatic hormone-naive prostate cancer to castration resistance after intensified hormonal therapy. The award period runs from April 1, 2023 through May 31, 2027. The funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to...